← All FDA warning letters

FDA Warning Letter · #717525

Boothwyn Pharmacy, LLC: FDA Warning Letter (January 16, 2026)

Boothwyn Pharmacy, LLC received this warning letter on January 16, 2026, from FDA’s Center for Drug Evaluation and Research (CDER). What it cites, and FDA’s own words where we matched them against the letter, are summarized below.

Issued January 16, 2026Status: activeCenter for Drug Evaluation and Research (CDER)On this register since August 16, 2026
By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

Primary Source

View the original FDA letter on fda.gov →

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/boothwyn-pharmacy-llc-717525-01162026

Summary

Company
Boothwyn Pharmacy, LLC
Letter number
#717525
Issue date
January 16, 2026
Subject
Compounding Pharmacy/Adulterated Drug Products

What FDA cited

FDA's letter of January 16, 2026 cites Boothwyn Pharmacy, LLC for manufacturing-practice (CGMP) violations, under the subject line "Compounding Pharmacy/Adulterated Drug Products". The GLP-1 drugs it names: semaglutide and tirzepatide.

In FDA’s words:
The FDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. … Furthermore, the FDA investigators noted that your firm released and distributed drug products that failed sterility testing. For example, your Tirzepatide 17mg/mL / Glycine 5mg/mL / Methylcobalamin 5mg/mL Injection (lot # 04072025@(b)(4)).

How this letter sits against the other 159

Our reading, from the 160 letters on this register — not part of the FDA’s document.

No other letter on this register carries the date January 16, 2026. The agency acted against this company on its own that day, which is uncommon here — most of the letters we hold arrived in sweeps.

A warning letter is the agency putting a company on notice, not a court finding and not a ban. What it is worth to you is in what it alleges, so read the original on fda.gov rather than the fact that one exists.

The FDA wrote about how this firm compounds. For what the 503A and 503B rules require: 503A vs 503B compounding pharmacies: who oversees your compounded GLP-1.

Our profile of Boothwyn Pharmacy covers the same operator.

FDA’s letter of May 1, 2026 to Harbin Jixianglong Biotech Co., Ltd. also cites its recipient for manufacturing-practice (CGMP) violations.

What FDA warning letters mean

It is the agency writing to a company to say it believes something that company is doing breaks the Federal Food, Drug, and Cosmetic Act — usually a claim on a website, a labeling choice, or how a drug is being made. The company has about fifteen working days to write back.

Read carefully what it is not. It is not a recall, not a criminal charge, and not a court deciding anyone broke the law. It is the regulator opening a file. Companies frequently answer a letter, fix what was cited, and carry on trading, and when FDA accepts that it can issue a close-out letter. We do not track close-outs, so the presence of a letter on this page tells you what FDA said on one date — not where the matter stands today. Ask the company; they will usually tell you, and how they answer is informative in itself.

Across this market the same three citations recur: claiming a compounded product is equivalent to an approved one, labeling that misleads, and compounding from bulk substances FDA has not cleared under sections 503A and 503B. If you are reading a letter here, it is probably one of those.

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.2

bmiMD

Starting below a standard dose, with microdose tiers

6.3

WellMedRx

Comparing compounded and brand GLP-1 plans with a published state list

7.1

Direct Meds

Compounded semaglutide at $249/month

Other warning letters in our database

View the full database →

Editorial Disclaimer

This is a public communication from a regulator, and by itself it settles nothing about whether the company broke any law. Corrective action is a common response, and a fair number of letters end in a close-out. Read the whole thing on fda.gov through the link above rather than taking our excerpt as the full picture.

Glossary

The words sellers use, defined. Tap any term.